taxane and 1-4-7-10-tetraazacyclododecane--1-4-7-10-tetraacetic-acid

taxane has been researched along with 1-4-7-10-tetraazacyclododecane--1-4-7-10-tetraacetic-acid* in 1 studies

Reviews

1 review(s) available for taxane and 1-4-7-10-tetraazacyclododecane--1-4-7-10-tetraacetic-acid

Article	Year
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert review of anticancer therapy, 2022, Volume: 22, Issue:11 Extensive experience outside the United States as well as randomized phase II and phase III data demonstrate that. This review discusses the development and studies leading to the approval of Topics: Clinical Trials, Phase II as Topic; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2022

Article

Year

Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.

Expert review of anticancer therapy, 2022, Volume: 22, Issue:11

Extensive experience outside the United States as well as randomized phase II and phase III data demonstrate that. This review discusses the development and studies leading to the approval of

Topics: Clinical Trials, Phase II as Topic; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome

2022